Clear Cell Renal Cell Carcinoma

Oncology
11
Pipeline Programs
12
Companies
48
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
5
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 9 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
PembrolizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06661720Recruiting1,040Est. Nov 2037
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
Cemiplimab 350 MG Intravenous SolutionPhase 21 trial
Active Trials
NCT07223541Recruiting72Est. Aug 2031
X4 Pharmaceuticals
2 programs
2
X4P-001Phase 1/21 trial
X4P-001Phase 1/21 trial
Active Trials
NCT02923531TerminatedEst. Aug 2018
NCT02667886CompletedEst. Apr 2022
Genentech
GenentechCA - Oceanside
1 program
1
BevacizumabPhase 1/2Monoclonal Antibody
CRISPR Therapeutics
1 program
1
CTX131Phase 1/21 trial
Active Trials
NCT05795595Completed19Est. Sep 2025
Novartis
NovartisBASEL, Switzerland
1 program
1
panobinostatPhase 1/2Small Molecule5 trials
Active Trials
NCT02568943No Longer Available
NCT02204553No Longer Available
NCT03982134Withdrawn0Est. May 2022
+2 more trials
Arrowhead Pharmaceuticals
1 program
1
ARO-HIF2Phase 11 trial
Active Trials
NCT04169711Completed26Est. Jul 2022
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
AdGMCAIX-transduced autologous dendritic cellsPhase 11 trial
Active Trials
NCT01826877Completed12Est. May 2021
Xencor
XencorPASADENA, CA
1 program
1
XmAb819Phase 11 trial
Active Trials
NCT05433142RecruitingEst. Dec 2028
Arcus Biosciences
1 program
1
casdatifanPhase 11 trial
Active Trials
NCT05536141RecruitingEst. Mar 2029
Pfizer
PfizerNEW YORK, NY
1 program
Investigating Patient Satisfaction With Oral Anti-Cancer TreatmentN/A1 trial
Active Trials
NCT02247583Completed90Est. Jul 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novartispanobinostat
Alliance PharmaceuticalsPembrolizumab
Novartispanobinostat
Novartispanobinostat
RegeneronCemiplimab 350 MG Intravenous Solution
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat
Novartispanobinostat

Showing 15 of 46 trials with date data

Clinical Trials (48)

Total enrollment: 3,677 patients across 48 trials

NCT02386800Novartispanobinostat

CINC424A2X01B Rollover Protocol

Start: Mar 2015Est. completion: Sep 2027279 patients
Phase 4Active Not Recruiting
NCT06661720Alliance PharmaceuticalsPembrolizumab

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Start: Mar 2025Est. completion: Nov 20371,040 patients
Phase 3Recruiting
NCT01034163Novartispanobinostat

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Start: Jun 2010Est. completion: May 201241 patients
Phase 3Completed
NCT01023308Novartispanobinostat

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Start: Dec 2009Est. completion: Jul 2015767 patients
Phase 3Completed
NCT07223541RegeneronCemiplimab 350 MG Intravenous Solution

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Start: Jan 2026Est. completion: Aug 203172 patients
Phase 2Recruiting
NCT02518750Novartispanobinostat

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Start: Nov 2016Est. completion: Mar 20183 patients
Phase 2Terminated
NCT02720510Novartispanobinostat

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Start: Jun 2016Est. completion: May 20176 patients
Phase 2Terminated
NCT01802879Novartispanobinostat

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Start: Jun 2013Est. completion: Nov 20189 patients
Phase 2Completed
NCT01651039Novartispanobinostat

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Start: Jul 2012Est. completion: Dec 201632 patients
Phase 2Completed
NCT01460940Novartispanobinostat

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Start: Oct 2011Est. completion: Nov 201624 patients
Phase 2Completed
NCT01056601Novartispanobinostat

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Start: Sep 2010Est. completion: Feb 20117 patients
Phase 2Terminated
NCT01083602Novartispanobinostat

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Start: Jun 2010Est. completion: Feb 201455 patients
Phase 2Completed
NCT01115036Novartispanobinostat

A Panobinostat Presurgery

Start: Apr 2010Est. completion: Apr 20120
Phase 2Withdrawn
NCT00931762Novartispanobinostat

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Start: Aug 2009Est. completion: Aug 201135 patients
Phase 2Terminated
NCT00742027Novartispanobinostat

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Start: Sep 2008Est. completion: Aug 2013129 patients
Phase 2Completed
NCT00667862Novartispanobinostat

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Start: Mar 2008Est. completion: Nov 201035 patients
Phase 2Completed
NCT05795595CRISPR TherapeuticsCTX131

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Start: Mar 2023Est. completion: Sep 202519 patients
Phase 1/2Completed
NCT02923531X4 PharmaceuticalsX4P-001

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Start: Dec 2016Est. completion: Aug 2018
Phase 1/2Terminated
NCT02471430Novartispanobinostat

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Start: May 2016Est. completion: Dec 202317 patients
Phase 1/2Completed
NCT02667886X4 PharmaceuticalsX4P-001

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Start: Apr 2016Est. completion: Apr 2022
Phase 1/2Completed
NCT02145715Novartispanobinostat

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Start: Jan 2013Est. completion: Jan 201654 patients
Phase 1/2Unknown
NCT01680094Novartispanobinostat

Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART

Start: Sep 2012Est. completion: Jan 201415 patients
Phase 1/2Completed
NCT01496118Novartispanobinostat

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Start: Dec 2011Est. completion: Dec 202080 patients
Phase 1/2Completed
NCT01169636Novartispanobinostat

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Start: Jan 2011Est. completion: May 201762 patients
Phase 1/2Completed
NCT01582009Novartispanobinostat

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Start: Mar 2010Est. completion: Dec 201526 patients
Phase 1/2Terminated
NCT00925132Novartispanobinostat

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Start: Dec 2009Est. completion: Dec 201639 patients
Phase 1/2Terminated
NCT00878436Novartispanobinostat

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Start: Jun 2009Est. completion: Jul 201552 patients
Phase 1/2Completed
NCT00567879Novartispanobinostat

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Start: Apr 2008Est. completion: May 201156 patients
Phase 1/2Terminated
NCT05536141Arcus Biosciencescasdatifan

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Start: Oct 2022Est. completion: Mar 2029
Phase 1Recruiting
NCT05433142XencorXmAb819

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Start: Jun 2022Est. completion: Dec 2028
Phase 1Recruiting
NCT04169711Arrowhead PharmaceuticalsARO-HIF2

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Start: Aug 2020Est. completion: Jul 202226 patients
Phase 1Completed
NCT03982134Novartispanobinostat

PDR001 + Panobinostat for Melanoma and NSCLC

Start: Sep 2019Est. completion: May 20220
Phase 1Withdrawn
NCT02890069Novartispanobinostat

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Start: Oct 2016Est. completion: Feb 2022298 patients
Phase 1Completed
NCT02032810Novartispanobinostat

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Start: Jan 2014Est. completion: Sep 201917 patients
Phase 1Completed
NCT01965353Novartispanobinostat

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Start: Oct 2013Est. completion: Sep 202121 patients
Phase 1Completed
NCT01440582Novartispanobinostat

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Start: Feb 2013Est. completion: Feb 201977 patients
Phase 1Completed
NCT01826877Gilead SciencesAdGMCAIX-transduced autologous dendritic cells

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

Start: Jan 2013Est. completion: May 202112 patients
Phase 1Completed
NCT01324635Novartispanobinostat

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Start: May 2012Est. completion: Oct 201617 patients
Phase 1Terminated
NCT01463046Novartispanobinostat

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Start: Jan 2012Est. completion: Dec 201829 patients
Phase 1Completed
NCT01433445Novartispanobinostat

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Start: Nov 2011Est. completion: Jun 202061 patients
Phase 1Completed
NCT01504776Novartispanobinostat

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Start: Apr 2011Est. completion: Sep 20143 patients
Phase 1Completed
NCT01336842Novartispanobinostat

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Start: Apr 2011Est. completion: Jun 201723 patients
Phase 1Completed
NCT01321346Novartispanobinostat

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Start: Mar 201130 patients
Phase 1Completed
NCT01238965Novartispanobinostat

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

Start: Oct 2010Est. completion: Apr 20157 patients
Phase 1Terminated
NCT00891033Novartispanobinostat

Panobinostat/Velcade in Multiple Myeloma

Start: Apr 2009Est. completion: Aug 201312 patients
Phase 1Terminated
NCT02568943Novartispanobinostat

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

N/ANo Longer Available
NCT02204553Novartispanobinostat

Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

N/ANo Longer Available
NCT02247583PfizerInvestigating Patient Satisfaction With Oral Anti-Cancer Treatment

Investigating Patient Satisfaction With Oral Anti-Cancer Treatment

Start: Feb 2011Est. completion: Jul 201390 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 3,677 patients
12 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)